Results 281 to 290 of about 2,867,692 (324)

Cyclooxygenase-2 selective inhibitors and the kidney

Current Opinion in Internal Medicine, 2001
Cyclooxygenases (COX) are the target of non-steroidal anti-inflammatory drugs (NSAIDs) which exert their therapeutic effect by blocking COX's capacity to metabolize arachidonate to a series of biologically active fatty acids, designated prostaglandins.
Matthew D. Breyer, Chuan-Ming Hao, Zhonghua Qi   +2 more
openaire   +4 more sources

Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation

European Journal of Pharmacology, 1998
The anti-inflammatory activity of drugs more selective for cyclooxgenase isoform inhibition (cyclooxygenase 1, cyclooxygenase 2), were compared in rat carrageenin-induced pleurisy. Suppression of inflammation by cyclooxygenase 2-selective inhibitors, NS-398 (N-[-2-cyclohexyloxy]-4-nitrophenyl methanesulphonamide) and nimesulide (4-nitro-2-phenoxy ...
Annette Tomlinson, Derek W. Gilroy, Derek A. Willoughby   +2 more
openaire   +3 more sources

The classification of cyclooxygenase inhibitors.

The Journal of rheumatology, 1998
Item does not contain ...
Lipsky, P.E., Abramson, S.B., Crofford, L.J., Dubois, R.N., Simon, L.S., Putte, L.B.A. van de   +5 more
openaire   +2 more sources

Rofecoxib: A specific cyclooxygenase inhibitor

Drugs of Today, 2000
Rofecoxib is a new specific cyclooxygenase-2 inhibitor. The efficacy of rofecoxib has been established in the treatment of osteoarthritis, rheumatoid arthritis and acute pain. Rofecoxib has been approved in the United States for the treatment of osteoarthritis and acute pain. Endoscopically proven gastrointestinal ulceration is much less with rofecoxib
openaire   +3 more sources

Thalidomide and its analogues as cyclooxygenase inhibitors

Bioorganic & Medicinal Chemistry Letters, 2002
Thalidomide showed cyclooxygenase (COX)-1/2 inhibitory activity with a potency comparable to that of aspirin. Structural development studies of thalidomide resulted in potent COX-1/2 inhibitors, and COX-1-selective and COX-2-selective inhibitors.
Rumiko Shimazawa, Kazuo Nagasawa, Tomomi Noguchi, Yuichi Hashimoto   +3 more
openaire   +3 more sources

Cyclooxygenase inhibitors

2013
Cyclooxygenase (COX) inhibitors are widely used to relieve musculoskeletal pain. COX inhibitors are a group of heterogenous substances including non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol (acetaminophen). Moreover, various selective cyclooxygenase-2 (COX-2) inhibitors with improved gastrointestinal tolerability as compared with ...
Burkhard Hinz, Kay Brune
openaire   +1 more source

Cyclooxygenase-2 Inhibitors in Lung Cancer

Clinical Lung Cancer, 2004
Prostanoids produced by the arachidonic acid pathway play an important role in multiple stages of carcinogenesis and progression of cancer. Cyclooxygenase (COX), which exists in 2 isoforms, is the rate-limiting enzyme in the COX pathway. Cyclooxygenase-1 is constitutively expressed in normal tissues and is essential for several important physiologic ...
Sakkaraiappan Ramalingam, Chandra P. Belani   +1 more
openaire   +3 more sources

Clinical experience with cyclooxygenase-2 inhibitors

Inflammation Research, 1999
Increasing amounts of experimental and clinical data support the role of selective cyclooxygenase (COX)-2 inhibition in anti-inflammatory processes and the role of COX-1 inhibition in increasing the frequency of side effects. This article reviews the regulation of COX-2 in inflammatory processes based on in vitro and in vivo work.
J. van Ryn, Michel Pairet
openaire   +3 more sources

The role of cyclooxygenase inhibitors in repair of ischaemic-injured jejunal mucosa in the horse.

Equine veterinary journal. Supplement, 2010
Cyclooxygenase inhibitors are administered to horses to prevent endotoxin-induced elaboration of prostaglandins. However, PGE2 and PGI2 stimulate repair of injured intestine.
N. Campbell, A. Blikslager
semanticscholar   +1 more source

Synthesis, anti-inflammatory activity, and in vitro antitumor effect of a novel class of cyclooxygenase inhibitors: 4-(aryloyl)phenyl methyl sulfones.

Journal of Medicinal Chemistry, 2010
Following our previous research on anti-inflammatory drugs (NSAIDs), we report on the design and synthesis of 4-(aryloyl)phenyl methyl sulfones. These substances were characterized for their capacity to inhibit cyclooxygenase (COX-1 and COX-2) isoenzymes.
Y. Harrak, Giovanni Casula, J. Basset, G. Rosell, S. Plescia, D. Raffa, M. Cusimano, R. Pouplana, M. Pujol   +8 more
semanticscholar   +1 more source